- Bristol-Myers Squibb Company stock price today and history
Bristol-Myers Squibb Company (BMY) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Bristol-Myers Squibb Company stock price
Bristol-Myers Squibb Company latest news:
BRIEF-Bristol-Myers announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer
Bristol-Myers Squibb Co(BMY). * Bristol-Myers Squibb Co(BMY) announced data evaluating Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer. * Bristol-Myers Squibb Co (BMY) says in patients with high tmb who received opdivo plus yervoy, 62% were alive at one year. * Bristol-Myers Squibb Co (BMY) says in patients with high tmb who received opdivo, 35% were alive at one year Sou...
BRIEF-Bristol-Myers Squibb says Karen Vousden elected as member of board
* Bristol-Myers Squibb Co - on Sept 13, board elected Karen
Vousden to serve as member of board; size of board was increased
to eleven - SEC filing
Source text: [http://bit.ly/2x04hcV]
Further company coverage:
U.S. stocks end mostly lower as financials sell off
U.S. stock-market indexes closed marginally lower on Thursday, led by a selloff in the financial and consumer discretionary sectors. Investors were also cautious as a potentially destructive Hurricane Irma headed toward Florida after battering a number of Caribbean islands. The Dow Jones Industrial Average fell 21.83 points, 0.1%, to 21,785.12, with JPMorgan Chase & Co and Travelers Companies, Inc leading losses, down nearly 2%. The S&P 500 slipped less than a point to 2,465.10. The Nasdaq Composite index eked out marginal gains, closing 4.55 points, or less than 0.1% higher at 6,397.87. Among the best performers on Wall Street were drug companies. AbbVie, Inc jumped 6%, Bristol-Myers Squibb Co rallied 5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Bristol-Myers Squibb says late-stage cancer drug combination study met endpoints and will be stopped early
Bristol-Myers Squibb Co. said early Thursday that a late-stage clinical trial for cancer drugs Opdivo and Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma showed better overall survival compared to chemotherapy in intermediate and poor risk patients. Overall survival was a co-primary endpoint of the trial; the cancer drug combination also showed to have improved overall survival compared with chemotherapy in all randomized patients, a secondary endpoint. The company said that an independent Data Monitoring Committee has recommended the trial be stopped early, based on a scheduled interim analysis. Renal cell carcinoma is the most common kidney cancer in adults, and the five-year survival rate for patients with metastatic or advanced kidney cancer is 12.1% globally, the company said. Bristol-Myers shares lifted 0.13% in premarket trade Thursday. Company shares have surged 13.9% over the last three months, compared with a 1.3% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201
* Bristol-Myers Squibb and Daiichi Sankyo announce research
collaboration to evaluate Opdivo (Nivolumab) and DS-8201 in
HER2-expressing breast and bladder cancers
Urban Outfitters and Agilent climb; Bristol-Myers skids
Urban Outfitters and Agilent Technologies trade higher while Bristol-Myers Squibb and Helmerich & Payne slip
Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
Bristol-Myers Squibb Co. shares declined in the extended session Tuesday after the drugmaker said one of the endpoints of a kidney cancer drug study was not met. Bristol-Myers Squibb shares fell 2.5% to $56.40 after hours. The company said that while a late-stage study of its use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Bristol-Myers to buy IFM Therapeutics for $300 million, and potential contingent payments
Bristol-Myers Squibb Co. announced Thursday a deal to buy privately-held biotechnology company IFM Therapeutics for $300 million, and contingent payments of up to $1.01 billion. The acquisition gives Bristol-Myers rights to preclinical programs, STING (stimulator of interferon genes) and NLRP3 agonist, which are focused on enhancing the innate immune response for treating cancer. IFM will also be entitled to additional payments of up to $1.01 billion for each of the first products from the two programs if certain development, regulatory and sales milestones are achieved. The deal is expected to close during the third quarter of 2017. "The addition of STING and NLRP3 agonist programs broadens our ability to investigate additional pathways across the immune system and complements our immuno-oncology portfolio," said Bristol-Myers's Chief Scientific Officer Thomas Lynch. Bristol-Myers's stock, which was inactive in post-market trade, has gained lost 5.0% year to date through Thursday, while the SPDR Health Care Select Sector ETF has run up 15.6% and the S&P 500 has climbed 10.4%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 3-Bristol-Myers shares slump after failed AstraZeneca drug trial
July 27 (Reuters) - Bristol-Myers Squibb Co shares
fell 4 percent on Thursday as investors bet that a failed
cancer-drug trial at AstraZeneca Plc would have negative
implications for Bristol-Myers' similar immunotherapy treatment
BRIEF-Bristol-Myers Squibb’s Orencia receives second European Commission approval
Bristol-myers Squibb Co(BMY). * Bristol-Myers SquibbS Orencia receives second European Commission approval in less than a year new approval for treatment of active psoriatic arthritis1. * Approval was based on results from two randomized, double-blind, placebo-controlled studies PSA-i and PSA-ii Source text for Eikon: Further company coverage:
Bristow Group IncBRS
Brixmor Property Group Inc.BRX
Broadridge Financial SolutionsBR
Brookdale Senior Living Inc.BKD
Brookfield Asset Management IncBAM
Brookfield Canada Office PropertiesBOXC
Brookfield DTLA Inc.DTLA^
Brookfield Global Listed Infrastructure Income FunINF
Brookfield High Income Fund Inc.HHY
Brookfield Infrastructure Partners LPBIP